STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
All sources
- STAT News · Center
Prism News is a free news aggregator that breaks every story into Left, Center and Right perspectives — see what each side covers, what they ignore, and how the same event gets framed differently.